Today's focus

[Jiu'an Healthcare: Subsidiary Jiu'an Hong Kong signs investment-related agreements with entities related to Dark Side of the Moon]

Jiu'an Medical issued a change announcement. In August 2023, Jiu'an Hong Kong, a wholly-owned subsidiary of the company, signed an investment-related agreement with entities related to Dark Side of the Moon, with an investment amount equivalent to about 10 million US dollars. In March 2024, Tianjin Jiushang No. 1 Management Consulting Partnership (Limited Partnership) (Jiu'an Hong Kong indirectly holds 98.68% of the partnership's share), which participated in the investment, signed an investment-related agreement with entities related to Dark Side of the Moon, with an investment amount equivalent to about 20 million US dollars. After the investment in Dark Side of the Moon is completed, the share ratio of the bid company is very low, and it is not expected to have a significant impact on the company's business situation and financial situation. Currently, artificial intelligence technology is still in the development stage, and there is great uncertainty.

[Zhongtai Chemical: The Securities Regulatory Commission decided to file a case against the controlling shareholder Zhongtai Group due to suspected illegal disclosure of information]

Zhongtai Chemical announced that the Securities Regulatory Commission decided to file a case against Zhongtai Group, the controlling shareholder of the company, on suspicion of organizing and directing listed companies to commit illegal acts of information disclosure.

Investments & Contracts

[Polytechnic University Hi-Tech: Signed a strategic cooperation agreement with Anhui University of Science and Technology]

Polytechnic University of Technology announced that recently, the company and Anhui University of Science and Technology decided to further cooperate in scientific and technological innovation, discipline construction, talent training, platform construction, etc. in fields such as coal mine safety production and intrinsically safe intelligent green mine construction, and signed a strategic cooperation agreement on cooperation intentions.

Changes in equity

[AGCO Technology: Plans to acquire 100% of ARISTO's shares in Germany to improve global layout]

AGCO Technology announced that in order to improve its global strategic layout and increase its share in the European and American markets, the company plans to acquire 100% of ARISTO Germany's shares through IECHO Asia Limited (“AGCO Asia”), a wholly-owned subsidiary, with a transaction consideration of about 3.7 million euros, or approximately RMB 28.774,500. After the transaction was completed, ARISTO Germany became a wholly-owned subsidiary of AGCO Asia, a wholly-owned subsidiary of the company. Currently, ARISTO Germany is Germany's leading manufacturer of intelligent cutting equipment. The intelligent cutting equipment produced by ARISTO Germany can be used for CAD/CAM processing of non-metallic materials.

Operation & Performance

[Huazhong CNC: Net profit increased 45.7% year-on-year in 2023, and plans to pay 0.2 yuan for 10]

Huazhong CNC released its annual report. In 2023, it achieved operating income of 2.115 billion yuan, a year-on-year increase of 27.13% (adjusted); net profit of 27.907 million yuan, a year-on-year increase of 45.7% (adjusted); and basic earnings per share of 0.14 yuan. The company plans to pay a cash dividend of 0.2 yuan (tax included) for every 10 shares.

[Huitai Healthcare: Net profit increased 49.13% year-on-year in 2023, and plans to distribute 20 yuan for 10 to 4.5 shares]

Huitai Medical released its annual report. In 2023, it achieved operating income of 1.65 billion yuan, an increase of 35.71% year on year; net profit of 534 million yuan, up 49.13% year on year; and basic earnings per share of 8.04 yuan. The company plans to increase 4.5 shares for every 10 shares and distribute a cash dividend of 20 yuan (tax included).

[Hang Seng Electronics: Net profit increased 30.5% year-on-year in 2023, and plans to split 10 to 1.3 yuan]

Hang Seng Electronics released its annual report. In 2023, it achieved operating income of 7.281 billion yuan, an increase of 11.98% year on year; net profit of 1,424 billion yuan, up 30.5% year on year; and basic earnings per share of 0.75 yuan. The company plans to pay 1.3 yuan in cash (tax included) for every 10 shares.

[Chuangyuan Co., Ltd. Performance Report: Net profit to mother of 76.5811 million yuan in 2023 increased 2.19% year-on-year]

Chuangyuan Co., Ltd. announced that the company's revenue for 2023 was 1,359 million yuan, up 3.04% from the same period last year; net profit attributable to common shareholders of listed companies was 76.5811 million yuan, up 2.19% from the same period last year. Basic earnings per share were $0.4214. The company strengthens marketing management, actively explores market opportunities through multiple channels, and promotes both the growth of the company's revenue and net profit.

[Skyrim Co., Ltd.: Net profit in 2023 fell 93.04% year-on-year, and plans to pay 10 yuan to pay 1 yuan]

Skyrim Co., Ltd. released its annual report. In 2023, it achieved operating income of 2,193 billion yuan, a year-on-year decrease of 33.03%; net profit of 36.6409 million yuan, a year-on-year decrease of 93.04%; and basic earnings per share of 0.09 yuan. The company plans to distribute a dividend of 1 yuan (tax included) for every 10 shares. During the reporting period, the price of lithium hexafluorophosphate followed changes in the price of lithium carbonate, and the price fluctuated sharply. Entering 2024, in January and February, the price of lithium hexafluorophosphate continued to fall, reaching a minimum of around 63,000 yuan per ton; in March, the price of lithium hexafluorophosphate began to rise as the price of lithium carbonate stopped falling and stabilized. Up to now, the price of lithium hexafluorophosphate has rebounded to more than 70,000 yuan per ton.

other

[Yifan Pharmaceutical: The holding subsidiary's products under development were approved for listing by the European Commission]

Yifan Pharmaceutical announced that its holding subsidiary Evive Biotechnology Ireland Limited has received the “Commission Implementation Resolution” issued by the European Commission to approve the marketing and sale of the company's ongoing product, abergastine α injection in the European Union.

[Lingda Co., Ltd.: Some bank accounts of the company and its subsidiaries have been frozen]

Lingda Co., Ltd. announced that the company recently learned through the depositary banking system that some bank accounts of the company and its subsidiary Jinzhai Jiayue have been frozen.

[China Communications Construction: Zhou Changjiang Resigns as Secretary of the Board of Directors and Company Secretary]

China Communications Construction announced that the company's board of directors received written resignation from Zhou Changjiang on March 22, 2024. Due to job transfers, Zhou Changjiang resigned from the company's board of directors as secretary of the board of directors and company secretary. The above resignations took effect immediately.